A UK-based startup has unveiled innovative technology capable of transforming the landscape of cancer diagnosis and treatment.
Astral Systems, a company founded by the University of Bristol, has demonstrated the use of a first-of-its-kind multi-state fusion (MSF) reactor.
It is designed to produce essential medical isotopes needed for cancer radiotherapy and diagnostic imaging.
Medical isotopes are radioactive substances used in medicine for a variety of diagnostic and therapeutic purposes.
According to the press release, these isotopes can play a vital role in targeted cancer treatment by effectively killing cancer cells during radiation therapy.
“Nuclear medicine has helped save lives for decades by enabling the medical profession to research cancer and directly treat tumors and cancer cells at the source,” said Talmon Firestone, co-founder and CEO of Astral. Systems and visiting researcher at the University of Bristol.
Gn En gealth